Skip to main content
. 2013 Jun;182(6):2071–2081. doi: 10.1016/j.ajpath.2013.02.029

Figure 1.

Figure 1

Prophylactic therapy with anti–IL-17A reduces clinical disability and reverses weight loss. A: Clinical scores in each group from PSDs 0 to 50. Scores in EAE animals treated with anti–IL-17A were significantly lower than those in mice treated with an IgG control. n = 10 in the control EAE, EAE+anti–IL-17A, and EAE+IgG groups; n = 3 in the naive group. Arrows indicate the day of antibody administration (PSD 1 dose not shown). B: Weight change in the groups from PSD 0 to 50. Compared with EAE+IgG-treated mice, EAE+anti–IL-17A–treated mice lost less weight during the acute phase, began to gain weight earlier, did not show prerelapse weight loss, and had significantly greater weight gain on PSDs 14 to 34. Data are shown as means ± SEM. ∗P < 0.05.